Icatibant Genus Pharmaceuticals (Icatibant)

Icatibant selectively blocks the bradykinin B2 receptor, preventing bradykinin from causing vasodilation and increased vascular permeability. This inhibition stops the fluid leakage that leads to the swelling seen in hereditary angioedema attacks.

The prescribed dose of Icatibant is determined by the treating physician based on the patient’s clinical condition and regulatory guidelines. The medication is supplied as a 30 mg/1 mL injection solution for subcutaneous administration.

The safety of Icatibant in pregnancy and while breastfeeding has not been established. Use is only recommended if the potential benefit justifies any possible risk to the mother or infant, and it should be decided by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑inhibitor concentrates and kallikrein inhibitors. Icatibant offers a subcutaneous route and rapid onset of action, making it suitable for self‑administration during acute attacks, while C1‑inhibitor products are typically given intravenously.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes.

Icatibant is administered as a single subcutaneous injection into the abdomen, thigh, or upper arm. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction. The site should be rotated for each dose to minimize local reactions.

The most serious risks include anaphylaxis, severe hypotension, and paradoxical angioedema unrelated to hereditary angioedema. Patients should be monitored for signs of allergic reaction, sudden blood pressure drops, or unexpected swelling, and seek immediate medical attention if these occur.

Icatibant is contraindicated in individuals with known hypersensitivity to the active ingredient or any excipients in the formulation. It should also be avoided in patients who are simultaneously receiving other bradykinin B2 antagonists or who have uncontrolled severe cardiovascular disease without medical supervision.